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PNEUMONIA Dr. M.Farz Mahdi, MD
Pneumonia DEFINITION
 Pneumonia is an infection of the pulmonary parenchyma. 
 Despite being the cause of significant morbidity and mortality
 Misdiagnosed
 Mistreated
 Underestimated

HCAP
 pneumonia as outpatients 
 multidrug-resistant (MDR) pathogens previously associated with HAP.
 risk factors for infection with MRSA independent of other MDR
CAP MDR pathogens;
 at least two, risk factors 
 probability of drug resistant pathogens 
 initial empirical broadspectrum antibiotic therapy
Risk Factors for Pathogens Resistant to Usual Therapy for CAP
 MULTIDRUG-RESISTANT GRAM-NEGATIVE BACTERIA AND MRSA
 Hospitalization ≥2 days in previous 90 days
 Use of antibiotics in previous 90 days
 Immunosuppression
 Nonambulatory status
 Tube feedings
 Gastric acid suppression
 Severe COPD or bronchiectasis
Risk Factors for Pathogens Resistant to Usual Therapy for CAP
 NOSOCOMIAL MRSA
 Hospitalization ≥2 days in previous 90 days
 Use of antibiotics in previous 90 days
 Chronic hemodialysis in previous 30 days
 Documented prior MRSA colonization
 Congestive heart failure
 Gastric acid suppression
Risk Factors for Pathogens Resistant to Usual Therapy for CAP
 COMMUNITY-ACQUIRED MRSA
 Cavitary infiltrate or necrosis
 Gross hemoptysis
 Neutropenia
 Erythematous rash
 Concurrent influenza
 Young, previously healthy status
 Summer-month onset
Causes :
proliferation of microbial pathogens at the alveolar level 
host’s response to those pathogens
Routes :
1- Oropharygeal aspiration ( aged & loss of consciousness)
2-Inhalation as contaminated droplets
3-Hematogen (e.g., from tricuspid endocarditis)
4-adjacent spread ( pleura & mediastinum)

HOST DEFENCE
 Hair and turbinate of the naire
 Mucus production and cilia; mucociliary escalator 
 Gag and cough reflex
 Normal bacterial flora
 Respiratory epithelial cells      defensins and cathelicidins
 Complement and IgA
 Macrophge
 Local proteins (surfactant proteins A and D)
 intrinsic opsonizing properties or antibacterial or antiviral activity
 engulfed by the macrophage


Inflammatory mediators
 interleukin 1 
 tumor necrosis factor
 GCSF
 stimulate the release of neutrophils 
 both peripheral leukocytosis and increased purulent secretions  
 Mediators released by macrophages 
 recruited neutrophils create an alveolar capillary leak 
 erythrocytes can cross the alveolar-capillary membrane          hemoptysis
Fever
capillary leak results from alveolar filling  
 radiographic infiltrate 
 Rales on auscultation
 hypoxemia
Dyspnea 
 Decreased compliance due to capillary leak
 Hypoxemia
 increased respiratory drive
 increased secretions
 occasionally infection-related bronchospasm
respiratory failure & death
 If severe enough
 intrapulmonary shunting of blood 



Pathology
 Stage 1 : Edema
 Stage 2 : Red Hepatization (bacteria, erythrocyte,neutrophil(
 Stage 3: Gray Hepatization (neutrophil, fibrin deposits, no bacteria(
 Stage 4 :Resolution
Stage 1 : Edema
 proteinaceous exudate
 often of bacteria in the alveoli
Stage 2 : Red Hepatization
 Erythrocytes in the cellular intraalveolar exudate 
 Neutrophil influx is more important 
 Bacteria are occasionally seen 
Stage 3 :Gray Hepatization
 no new erythrocytes are extravasating & lysed and degraded
 neutrophil is the predominant cell
 fibrin deposition is abundant
 Bacteria have disappeared
Stage 4: Resolution
 macrophage reappears as the dominant cell type in the alveolar space
 debris of neutrophils, bacteria, and fibrin has been cleared

PATHOLOGY
 lobar pneumococcal pneumonia 
 viral or Pneumocystis pneumonia
 viral and Pneumocystis pneumonias 
 Alveolar rather than interstitial processes
 In VAP, respiratory bronchiolitis
 microaspiration mechanism
 bronchopneumonia
 most common in nosocomial pneumonias
 Lobar pattern 
 more common in bacterial CAP
CAP ETIOLOGY
 Bacteria
 Fungi
 Viruses
 Protozoa
 Newly identified pathogens
 Metapneumoviruses
 coronaviruses responsible for SARS 
 Middle East respiratory syndrome
 community-acquired strains of MRSA 

CAP “typical” or “atypical” organisms 
 Streptococcus pneumoniae
 Haemophilus influenza
 S. aureus
 Klebsiella pneumoniae and Pseudomonas aeruginosa
 Mycoplasma pneumonia
 Chlamydia pneumonia
 Legionella species 
 Respiratory viruses 
 influenza viruses, adenoviruses, human metapneumovirus, RSV
 ∼10–15% of CAP cases that are polymicrobial
 “atypical”           macrolide, a fluoroquinolone, or a tetracycline
“typical” 
“atypical”
Anaerobes
 episode of aspiration
 days to weeks before presentation of pneumonia 
 combination of an unprotected airway 
 alcohol or drug overdose or a seizure disorder
 significant gingivitis
 Anaerobic pneumonias are often complicated 
 abscess formation 
 significant empyemas
 parapneumonic effusions
S. aureus pneumonia 
HCAP
CA-MRSA
 complicate influenza infection
 MRSA 
 primary etiologic agent of CAP
 Uncommon
 serious consequences, such as necrotizing pneumonia  


Epidemiologic factors Suggesting Possible Causes of CAP
COPD and/or smoking 
 Pseudomonas aeruginosa
 S. pneumonia
Epidemiologic factors Suggesting Possible Causes of CAP
Structural lung disease (e.g.,bronchiectasis)
 P. aeruginosa
 Burkholderia cepacia
 Staphylococcus aureus
Epidemiologic factors Suggesting Possible Causes of CAP
Dementia, stroke, decreased level of consciousness
 Oral anaerobes
 gram-negative enteric bacteria
Epidemiologic factors Suggesting Possible Causes of CAP
Lung abscess 
 CA-MRSA
 Oral anaerobes
 Endemic fungi 
 M. tuberculosis
 Atypical mycobacteria
Risk factors for CAP 
 Alcoholism
 Asthma
 Age of ≥70 years
 decreased cough 
 gag reflexes 
 reduced antibody and Toll-like receptor responses
 Immunosuppression
 Institutionalization



Enterobacteriaceae
 recently been hospitalized 
 received antibiotic therapy
 comorbidities such as alcoholism, heart failure, or renal failure
 Salmonella
 Escherichia coli
 Yersinia pestis
 Klebsiella
 Shigella
 Proteus
 Enterobacter
 Serratia
 Citrobacter
P. aeruginosa
Severe structural lung disease
Bronchiectasis
cystic fibrosis
Severe COPD
Clinical Presentation
 Fever
 altered general well-being
 respiratory symptoms, such as 
 cough (90%)
 sputum production (66%)
 dyspnea (66%)
 pleuritic pain (50%)
 hemoptysis (15%) 
CLINICAL MANIFESTATIONS
 mild to fatal in severity
 constitutional findings 
 limited to the lung & associated structures
 frequently febrile with tachycardia 
 history of chills and/or sweats
 Cough 
 Nonproductive or productive of mucoid, purulent, or blood-tinged sputum  
 Gross hemoptysis is suggestive of CA-MRSA pneumonia 
CLINICAL MANIFESTATIONS
 Depending on severity
 able to speak in full sentences 
 very short of breath
 If the pleura is involved
 pleuritic chest pain
 Up to 20% gastrointestinal symptoms 
 nausea, vomiting, and/or diarrhea
 Other symptoms 
 fatigue, headache, myalgias, and arthralgias
physical examination 
 degree of pulmonary consolidation 
 presence or absence of a significant pleural effusion
 An increased respiratory rate 
 use of accessory muscles of respiration 
 Palpation may reveal increased or decreased
 tactile fremitus
 percussion 
 reflecting underlying consolidated lung and pleural fluid 
dull to flat
physical examination (auscultation)
 Crackles
 bronchial breath sounds
 possibly a pleural friction rub
 not be so obvious in the elderly
 Severely ill patients may have septic shock and evidence of organ failure
Diagnosis of pneumonia
 In older patients                       multiple comorbidities
 general weakness
 decreased appetite
 altered mental status
 Incontinence
 decompensation due to underlying disease
especially
Diagnosis of pneumonia
 The presence of tachypnea 
 precede other signs of pneumonia by 1 to 2 days
 Tachycardia 
 Fever is absent in 30% to 40% of older patients  
 diagnosis of CAP is frequently delayed in older adults
 altered mental status without fever 
Relative Bradycardia with pneumonia due to
 Legionella
 C. psittaci
 Mycoplasma
 F. tularensis
DIAGNOSIS
 Is this pneumonia?
 clinical and radiographic methods
 likely etiology?
 aid of laboratory techniques
Clinical Diagnosis 
differential diagnosis 
 Infectious
 acute bronchitis
 acute exacerbations of chronic bronchitis
 Noninfectious 
 heart failure
 pulmonary embolism
 Hypersensitivity pneumonitis
 radiation pneumonitis
Clinical Diagnosis 
 careful history 
 known cardiac disease
 may suggest worsening pulmonary edema
 underlying carcinoma
 may suggest lung injury secondary to irradiation
Clinical Diagnosis 
physical examination 
 sensitivity 58% 
 specificity 67%
 chest radiography is often necessary to differentiate CAP 
Radiographic findings 
 risk factors for increased severity 
 cavitation 
 multilobar involvement
 Occasionally, radiographic results suggest an etiologic diagnosis
 pneumatoceles
 suggest infection with S. aureus
 upper-lobe cavitating lesion 
 suggests tuberculosis
 CT may be of value in a patient with suspected postobstructive
Radiographic findings CTscan
 suspected postobstructive pneumonia 
 tumor 
 foreign body 
 suspected cavitary disease 
For outpatients
 clinical and radiologic assessments 
 laboratory results are not available soon enough 
 rapid diagnosis of influenza virus infection 
 specific anti-influenza drug treatment and secondary prevention
Etiologic Diagnosis 
 clinical presentation?
 Except for CAP
 patients admitted to the ICU
 Treatment directed at a specific pathogen 
 superior to empirical therapy?
 Identification of an unexpected pathogen 
 narrowing of the initial empirical regimen
 decreasing antibiotic selection 
 lessening the risk of resistance
Etiologic Diagnosis 
 Pathogens with important public safety implications
 Mycobacterium tuberculosis 
 Influenza virus
 without culture and susceptibility data
 Resistance? 
 Appropriate empirical therapeutic? 
Gram’s stain and Culture of sputum 
 Gram’s staining 
 S. pneumonia 
 S. aureus
 gram-negative bacteria
Gram’s stain and Culture of sputum 
 sputum sample per low-power field
 >25 neutrophils
 <10 squamous epithelial cells

 Even in cases of proven bacteremic pneumococcal pneumonia
 Yield of positive cultures from sputum samples is ≤50%
DIAGNOSIS AND DIFFERENTIAL DIAGNOSIS
Sputum Examination
 >10 squamous epithelial cells per low-power field (×100 magnification)
specimen should be discarded
No squamous cells 
Many polymorphonuclear white blood cells (>25 cells/low-power field
Gram’s stain and Culture of sputum 
 ICU and intubated
 deep-suction aspirate or bronchoalveolar lavage
 high yield on culture 
 etiologies in severe CAP 
 staining and culturing respiratory secretions 
 unsuspected and/or resistant pathogens 
 specific stains for M. tuberculosis or fungi 
Blood Cultures? 
 low yield and the lack of significant impact on outcome
 disappointingly low Only 5–14% hospitalized with CAP are positive
 most frequently isolated pathogen is S. pneumonia 
Certain high-risk patients
 Neutropenia secondary to pneumonia
 Asplenia
 Complement deficiencies
 Chronic liver disease
 Severe CAP
urinary antigen tests 
 pneumococcal antigen in urine 
 sensitive and specific (80% and >90%)
 Legionella antigen in urine 
 sensitive and specific (90% and 99%)
 only serogroup 1
 detect antigen even after the initiation of appropriate antibiotic therapy
Polymerase chain reaction (PCR) tests
amplify a microorganism’s DNA or RNA
PCR of nasopharyngeal swabs 
Respiratory viral infection
Legionella species
M. pneumonia 
C. pneumonia
Mycobacteria
Serology  
 A fourfold rise in specific IgM antibody titer 
 Between acute- and convalescent-phase serum samples 
 In the past 
 Atypical pathogens 
 Unusual organisms such as Coxiella burnetii
 Recently, fallen out of favor 
Biomarkers
C-reactive protein (CRP)
Procalcitonin (PCT)
particularly to bacterial pathogens
Biomarkers
C-reactive protein (CRP)
worsening disease or treatment failure
Procalcitonin (PCT)
need for antibacterial therapy
physical examination, radiology, and laboratory tests


M. pneumoniae
Extrapulmonary manifestations M. pneumoniae    
 Arthralgia
 Cervical lymphadenopathy
 Bullous myringitis
 Diarrhea
 Myalgia
 Myocarditis
 Hepatitis
 Nausea
 Pericarditis
 Vomiting
CHLAMYDOPHILA 
PSITTACI PNEUMONIA
Pneumonia Severity Index 
(PSI)
 20 variables
 Age
 coexisting illness
 Abnormal physical findings
 Abnormal Laboratory findings
CURB-65 score 
Confusion
Urea >7 mmol/L 
Respiratory rate ≥30/min 
Blood pressure, 
 systolic ≤90 mmHg or diastolic ≤60 mmHg 
Age ≥ 65 years  
CURB-65 criteria 30-day mortality rate  
score of 0, 1.5%, treated outside the hospital
score of 2, 9.2%, should be admitted to the hospital
scores of ≥3, 22% overall; require ICU admission
Septic shock 
respiratory failure 
indication for ICU care

ANTIBIOTIC RESISTANCE
For CAP 
S. pneumoniae
CA-MRSA
INITIAL ANTIBIOTIC MANAGEMENT
 Empirical
 cover the most likely pathogens 
 should be initiated as expeditiously as possible
Outpatients
1. Previously healthy and no antibiotics in past 3 months
 Macrolide (clarithromycin or azithromycin) 
or
 Doxycycline 
Outpatients
2. Comorbidities or antibiotics in past 3 months: 
 respiratory fluoroquinolone (moxifloxacin ,gemifloxacin, levofloxacin) 
or
 β-lactam high-dose  
 amoxicillin [1 g tid] 
 amoxicillin/clavulanate [2 g bid]
 alternatives: 
 Ceftriaxone [1–2 g IV qd], 
 Cefpodoxime [200 mg PO bid]  
 Cefuroxime [500 mg PO bid])
plus a macrolide
Inpatients, Non-ICU
 A respiratory fluoroquinolone (moxifloxacin or levofloxacin)
 OR
 A β-lactam (ceftriaxone, ampicillin, cefotaxime, ertapenem) 
plus 
 Macrolided
 clarithromycin 
 azithromycin 
 or IV azithromycin
Inpatients, ICU
 A β-lactame
 ceftriaxone [2 g IV qd]
 ampicillin-sulbactam [2 g IV q8h],
 cefotaxime [1–2 g IV q8h]) 
plus 
 Azithromycin  
 or 
 Fluoroquinolone
Special Concerns
If Pseudomonas is a consideration:
 An antipseudomonal β-lactam 
 piperacillin/tazobactam [4.5 g IV q6h] 
 cefepime [1–2 g IV q12h]
 imipenem [500 mg IV q6h]
 meropenem [1 g IV q8h]) 
Plus  
 ciprofloxacin (400 mg IV q12h) or levofloxacin (750 mg IV qd)
Special Concerns
If Pseudomonas is a consideration:
 An antipseudomonal β-lactam 
 piperacillin/tazobactam [4.5 g IV q6h] 
 cefepime [1–2 g IV q12h]
 imipenem [500 mg IV q6h]
 meropenem [1 g IV q8h]) 
Plus  
 aminoglycoside (amikacin [15 mg/kg qd] or tobramycin [1. 7 mg/kg qd]) 
Plus  
 azithromycin
Special Concerns
If Pseudomonas is a consideration:
 An antipseudomonal β-lactam 
 piperacillin/tazobactam [4.5 g IV q6h] 
 cefepime [1–2 g IV q12h]
 imipenem [500 mg IV q6h]
 meropenem [1 g IV q8h]) 
Plus  
 aminoglycoside (amikacin [15 mg/kg qd] or tobramycin [1. 7 mg/kg qd]) 
Plus  
 Antipneumococcal fluoroquinolone
Special Concerns
If CA-MRSA is a consideration:
Add 
linezolid (600 mg IV q12h) 
or 
vancomycin (15 mg/kg q12h) 
Special Concerns
For penicillin allergic patients:
use a respiratory fluoroquinolone
and 
aztreonam (2 g IV q8h)

Skin lesions 
Erythema multiforme or Erythema nodosum
 Mycoplasma infection (as well as tuberculosis and endemic fungal)
 Ecthyma gangrenosum are most often seen with P. aeruginosa
Laboratory Evaluation
 blood cell counts
 serum glucose 
 electrolyte 
 pulse oximetry or arterial blood gas assays
 HIV testing, particularly in patients with no other risk factors for CAP 
Marked leukocytosis with a leftward shift 
 S. pneumoniae
 H. influenza
 gram-negative bacilli 
 M. pneumoniae
 Chlamydophila species
 Coxiella
 nonbacterial causes of pneumonia
than 
with 
Lobar pneumonia due to pneumococcus
Atypical pneumonia due to adenovirus
Aspiration pneumonia
دهیدراتاسیون
نوتروپنی شدید در زمینه پنومونی 
ساعت اول شروع بیماری مورد ارزیابی قرار می گیرند 42که در  بیمارانی 
“typical” CAP 
 bacteria such as S. pneumoniae, H. influenzae, and K. pneumonia  
 Acute
 Intense chill
 Productive cough 
 sputum is purulent or bloody. 
 Pleuritic pain may suggest S. pneumoniae. 
 Physical examination reveals typical findings of pulmonary consolidation 
 Blood tests show leukocytosis with neutrophilia
 presence of band forms 
 Chest radiography shows lobar consolidation with air bronchograms
“atypical pneumonia” 
 gradual onset of fever
 nonproductive cough
 relatively normal white blood cell count 
 without a readily demonstrable bacterial pathogen 
 systemic complaints are more prominent than the respiratory ones
 M. pneumoniae, Chlamydophila species, C. burnetii, and viruses  
 current guidelines do not emphasize the use of the typical versus atypical 
classification to determine initial empirical antibiotic treatment for CAP
Sputum Gram stain
 S. pneumoniae is a gram-positive coccus
 Pairs and chains; lancet shaped
 H. influenzae is a pleomorphic gram-negative rod
 S. aureus is a gram-positive coccus that forms “grape-like” clusters
 M. catarrhalis is gram-negative diplococcus
Sputum Gram stain
 Mycoplasma
 Legionella
 Mycobacterium
 Chlamydophila
Not seen on the sputum Gram stain
 Mycobacteria are seen with special acid-fast staining
Mycoplasma pneumoniae pneumonia: 
unilateral bronchopneumonia
Methicillin-resistant Staphylococcus aureus pneumonia
Klebsiella pneumoniae 
Pseudomonas 
aeruginosa
Legionella pneumophila pneumonia: 
multilobar pneumonia
کامًلا پاک نشده باشد اگر  8-6رادیوگرافی قفسه سینه بیماران دچار پنومونی مولتی لوبار تا هفته 
.باید حداقل پیشرفت به سمت بهبود را نمایان سازد
.پاک نشود نیازمند بررسی های بیشتری است8-6انفیلترایی که تا هفته  
نظرداشتدر انفیلترایی که پاک نمی شود می بایست کانسر ریه را در معموًلا 
A.P
Prevalence
 More common in children less than 4 and adults older than 60
Differential Diagnosis
 Acute bronchitis
 COPD exacerbation
Mimic Community-Acquired Pneumonia
 Pulmonary edema
 Pulmonary infarction (PTE)
 ARDS
 Pulmonary hemorrhage
 Lung cancer or metastatic cancer
 Atelectasis
 Radiation pneumonitis
 Drug reactions involving the lung
 Extrinsic allergic alveolitis
 Pulmonary vasculitis (WG)
 Pulmonary eosinophilia
 Organizing pneumonia
Complications
 Metastatic infections
 Abscess formation ( staph. , CA-MRSA, Pseudomona (
 Pleural effusion

Lung abscess
CA-MRSA, oral anaerobes, endemic fungi, M. tuberculosis, atypical mycobacteria
Pneumococcal bronchopneumonia
patchy bronchovascular thickening (arrows) in the LLL
trace blunting of the left costophrenic angle is present  
B, Axial chest CT 2 days following A shows 
nodular lingular consolidation (arrow) 
numerous small centrilobular nodules (arrowheads) 
consistent with bronchopneumonia. 
OUTCOME
 Fever resolves in 2 days
 Leukocytosis resolve in 4 days
 CXR  would be normal in 4-12 weeks
 Any patient should take a CXR 4-6 weeks after treatment
 If pneumonia reoccurs in same lobe a neoplasm or foreign body must be 
ruled out.
 If pneumonia reoccurs in different lobes an immunocompromised state 
must be ruled out.

